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ABSTRACT
The front-line treatment for depression are SSRIs 
(selective serotonin reuptake inhibitors). They prevent 
the removal of serotonin, a neurotransmitter, from the 
synapse by inhibiting pre-synaptic reuptake proteins. 
Many patients taking SSRIs often report significant 
weight fluctuation and changes in appetite, which can be 
linked to disturbances of the gut microbiota. For 
instance, SSRIs may be responsible for depleting weight 
regulating bacteria, increasing the chances of dysbiosis, 
or imbalance of the gut microbial community. Aside 
from weight fluctuations, SSRIs might be having a 
direct impact on gut microbial community structure, a 
change that results in a signal via the gut-brain axis that 
alleviates depressive episodes.
The goal of this ongoing project is to investigate if 
SSRIs have a direct significant effect on human gut 
microbial populations. This can be accomplished 
through in vitro drug administration provided to isolated 
human gut microbial communities in an anaerobic 
environment. 
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METHODS
1. Collection of microbes
I. Microbes were obtained from stool samples of 
healthy male donors not taking SSRIs.
2. Preparation of SSRIs: 3 SSRIs- Paroxetine (Paxil), 
Fluoxetine (Prozac) and Citalopram (Lexapro)- were 
dissolved in solvent DMSO to yield 1000x stock 
solutions.
3. Drug administration to gut microbiota in vitro
I. 6 conditions per drug, outlined in Figure 1.
II. Contents of tubes were incubated in an anaerobic 
chamber over 5 days. 
III. Samples from each tube were aliquoted at 24-
hour increments.
IV. After samples were taken, 1.25 mL BHI was 
added back to each culture tube to replace the 
volume lost. Tube 3 received 12.5 μL DMSO 
and tubes 4-6 received half of the amount of 
drug initially provided.
V. All samples were placed in a -80 degrees Celsius 
freezer for later use.
VI. All drugs were tested in triplicate with Figure 1 
set-up.
4. DNA extraction (current stage)
I. Samples are thawed and DNA extraction protocol 
is used with a Homebrew Kit to extract DNA
II. DNA concentration is assessed via a NanoDrop
spectrophotometer. 
5. DNA sequencing and bioinformatic analysis (future 
steps)
I. DNA samples will be sent to the Loyola 
Genomics Facility for 16S rRNA gene 
amplification.
II. Changes to the microbial communities with each 
set of trials will be assessed.
1: Negative Control: BHI
2: Positive Control: BHI, bacteria
3: Solvent Control: BHI, bacteria, DMSO
4: 0.1x: BHI, bacteria, 0.1x drug
5: 1x: BHI, bacteria, 1x drug
6: 10x: BHI, bacteria, 10x drug
1 2 3 4 5 6
At t=0, all tubes received 2.5 mL BHI growth media. Additionally, 
tubes 2-6 received 50 μL of the same microbial community. As the 
solvent control, tube 3 received 25 μL DMSO. Tubes 4, 5, and 6 
received 0.25 μL, 2.5 μL , and 25 μL SSRI, respectively. 
INTRODUCTION
SSRIs block the reuptake of serotonin via transport 
proteins on the axon terminals of serotonergic neurons, 
allowing more serotonin to stay in the synaptic cleft and 
continue to bind to the post-synaptic cells. 
The term ‘microbiome’ refers to the essential 
microbes that live in and on the human body8. The gut 
microbial community serves many functions, including 
regulation of body weight and maintaining a balanced 
environment3. Contemporary research has established a 
two-way connection between the nervous system and 
the gut microbiota, referred to as the microbiota gut-
brain axis (MGB axis) 2,5. Recent studies have found 
that the gut microbiota can have profound effects on the 
brain in terms of physiology, behavior, and cognition7. 
SSRIs may have unspecified effects in the intestinal 
tract. This project seeks to determine if SSRIs are 
directly causing any changes to gut microbial 
populations, and if so, how these changes could impact 
patients with depression who take SSRIs.
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PREDICTED RESULTS
Others who have studied the effects of Fluoxetine 
(Prozac) on murine gut microbial communities found 
increases in bacterial populations that are involved in 
dysbiosis. They also found decreases in populations of 
Lactobacillus johnsonii and Bacteroidales S24-7, 
bacteria belonging to phyla that play an important role 
in regulating body mass3. It is likely that the data 
gathered from these sets of experiments will yield 
similar results. Although I have used drugs of the same 
class, it may or may not be the case that administration 
of each of the SSRIs yields unique fluctuations. 
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Figure 1: Breakdown of Culture Tube 
Contents For Each SSRI
MATERIALS/NOTABLE 
EQUIPMENT
Coy Anaerobic Chamber 
NanoDrop Spectrophotometer
